This clinical trial is focused on studying treatments for Chronic Hepatitis B Virus Infection, a long-term infection of the liver caused by the hepatitis B virus. The study will explore the safety, tolerability, and effectiveness of different treatment combinations. The treatments being tested include VIR-2218, VIR-3434, and PEG-IFNα. VIR-2218 and VIR-3434 are solutions for injection, with VIR-2218 containing the active substance elebsiran and VIR-3434 containing tobevibart, a type of protein known as a monoclonal antibody. PEG-IFNα, also known as Pegasys, contains the active substance peginterferon alfa-2a and is also administered as an injection.
The purpose of this study is to evaluate how well these treatments work and how safe they are for people with chronic hepatitis B. Participants in the study will receive one or more of these treatments, or a placebo, over a period of up to 48 weeks. The study will monitor participants for any side effects and measure the effectiveness of the treatments in reducing the presence of the virus in the body. The study aims to find out if these treatments can help achieve a functional cure, which means the virus is no longer detectable in the blood and the liver functions normally.
Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also look at how the treatments affect specific markers of the virus in the blood, such as the levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA. The ultimate goal is to find a treatment regimen that is both safe and effective in managing or potentially curing chronic hepatitis B infection.



Germany
Romania